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Background: Nonagenarians are mostly denied from different therapeutic strategies due to high comorbidity index
and risk-benefit calculation. We present the results of nonagenarians with high comorbidity index not eligible for
conventional aortic valve surgery undergoing transcatheter aortic valve implantation (TAVI) with the CoreValve system.
Methods: Our retrospective analysis include baseline parameters, procedural characteristics, morbidity, mortality as well
as twelve-lead surface ECG and echocardiographic parameters which were revealed preinterventionally, at hospital
discharge and at 30-day follow-up. Clinical follow-up was performed 6 months after TAVI.
Results: Out of 158 patients 11 nonagenarians with a mean age of 92.6 ± 1.3 years suffering from severe aortic valve
stenosis and elevated comorbidity index (logistic EuroSCORE of 32.0 ± 9.5%, STS score 25.3 ± 9.7%) underwent TAVI
between January 2008 and January 2011 using the third-generation percutaneous self-expanding CoreValve prosthesis.
Baseline transthoracic echocardiography reported a mean aortic valve area (AVA) of 0.6 ± 0.2 cm2 with a mean and
peak pressure gradient of 60.2 ± 13.1mmHg and 91.0± 27.4mmHg, respectively. The 30-day follow up
all cause and cardiovascular mortality was 27.3% and 9.1%, respectively. One major stroke (9.1%), 2 pulmonary
embolisms (18.2%), 1 periprocedural (9.1%) and 1 (9.1%) spontaneous myocardial infarction occured. Life-threatening or
disabling bleeding occurred in 2 cases (18.2%), and minor bleeding in 7 cases (63.6%). Mean severity of heart failure
according to NYHA functional class improved from 3.2 ± 0.8 to 1.36 ± 0.5 while mean AVA increased from
0.6± 0.2cm2 to 1.8 ± 0.2cm2. At 6-months follow-up 8 patients (72.7%) were alive without any additional myocardial
infarction, pulmonary embolism, bleeding, or stroke as compared to 30-day follow-up.
Conclusion: Our case series demonstrate that even with elevated comorbidity index, clinical endpoints and
valve-associated results are relatively favorable in nonagenarians treated with CoreValve.
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Aortic valve stenosis (AS) is the most common native
valve disease, becoming more prevalent with the
ageing population [1]. The only definitive therapy for
patients with severe symptomatic AS consists of surgi-
cal valve replacement [1]. However, conventional valve
surgery is associated with high mortality and morbid-
ity for some patients due to high comorbidity index.* Correspondence: Ibrahim.akin@med.uni-rostock.de
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reproduction in any medium, provided the orThis leads to conservative management of these
patients despite the poor prognosis associated with
medical therapy [2]. Since its introduction in 2002 [3],
TAVI proves to be a robust technique in the treatment
of severe symptomatic AS in high surgical risk
patients [4-7]. This study firstly evaluated the out-
comes of TAVI in nonagenarians presenting a comor-
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generation percutaneous self-expanding CoreValve pros-
thesis (Medtronic, Minneapolis, MN, USA) were identified
for this case series. The criteria for inclusion and exclu-
sion to the TAVI procedure have been described else-
where [4-7]. In brief, patients were included with
echocardiographic measurements demonstrating severe
native valvular AS with an area < 1cm2, or < 0.6cm2/m2
regardless of adjunct regurgitation; a diameter of the basal
orifice of the stenosed valve between 20mm and 27mm;
and a diameter at the sinutubular junction≤ 43mm. Most
importantly, all patients were considered unfit for open
surgery with an EuroSCORE ≥ 20% [4,8]. TAVI was sug-
gested in agreement between a cardiac surgeon and both,
a clinical and interventional cardiologist; patient’s or
referring physician’s preference was not relevant. Treat-
ment strategy was in compliance with the Helsinki
Declaration. Our local ethics committee approved this
treatment strategy. Patients gave informed consent prior
TAVI. Pacemaker implantation at follow-up was consid-
ered indicated in case of complete AV block and type II
second-degree AV block.
Procedure
Details of the implantation procedures have been described
elsewhere [4-7]. In brief, all patients were operated in a
hybride interventional suite under general anaesthesia to
assure stable hemodynamics and minimize patient move-
ment during valve implantation. TAVI was performed via
femoral access under fluoroscopic imaging by using the
ProStar XL system (Abbott Vascular, Illinois, USA). The
aortic valve was initially dilated using a standard valvulo-
plasty balloon (18-25mm x 40-100mm) with a nominal
diameter slightly (2-6mm) smaller than the aortic valve
and followed by CoreValve insertion [4-7] and in case of
residual aortic insufficiency a post-TAVI balloon dilatation
to ensure complete apposition. After procedure patients
were transferred to intensive care unit (ICU). To assess
conduction disorders, ECG monitoring was continuously
performed over 7 days. All patients were prophylactically
given a temporary pacemaker via femoral venous access;
with VVI mode the active pacing was 40bpm.
Definitions
Definitions of all clinical outcomes were performed ac-
cording to the Valve Academic Research Consortium [9].
Statisitical methods
All data were processed using the SPSS statistical pack-
age for windows, release 16.0 (Chicago, Illinois, USA).
The descriptive statistical characteristics for quantitative
parameters are listed for normally distributed data in
mean ± standard deviation and in non-normally distrib-
uted data in median with interquartile range.Results
Out of 158 patients a total of 11 nonagenarians with a
mean age of 92.6 ± 1.3 years underwent TAVI at our
institution from January 2008 to January 2011. Clinical
presentation was dominated by dyspnoe (100%), angina
(36.4%), syncope (36.4%) and acute heart failure (45.5%).
The mean New York Heart Association (NYHA) func-
tional class was 3.2 ± 0.8. Many patients suffered from
high comorbidity index resulting in a mean logistic Euro-
SCORE of 32.0 ± 9.5% and a STS score of 25.3 ± 9.7%
(Table 1). Baseline transthoracic echocardiography reported
a mean AVA of 0.6± 0.2 cm2 with a mean and peak pres-
sure gradient of 60.2± 13.1mmHg and 91.0±27.4mmHg,
respectively. Out of 11 patients 9 (81.8%) had mild and
1 (9.1%) had moderate aortic regurgitation, respectively.
The analysis of ECGs revealed sinus rhythm in 8 patients
(72.7%) and atrial fibrillation in 1 individual (9.1%)
(Table 2).
TAVI was successfully performed in all patients (100%)
and no conversion to surgical AVR was necessary. In 2
cases we had an embolization of the valve. In both cases
the valves were not completely released and thus were
re-captured and implanted in a proper position. Mean
procedure and fluoroscopy time was 110.3 ± 29.5min
and 16.0 ± 6.8min, respectively. Mean ICU stay was
3.36 ± 1.9 days, whereas mean hospital stay was 18.5 ± 5.4
days (Table 3).
All cause and cardiovascular mortality was 18.2% (n= 2)
and 9.1% (n = 1), respectively. One major stroke (9.1%),
1 minor stroke (9.1%) and 2 TIAs (18.2%) occurred.
One patient each (9.1%) experienced a periprocedural
(<72h) myocardial infarction and a spontaneous myo-
cardial infarction, whereas 1 patient (9.1%) was in need
for new hemodialysis. Life threatening or disabling bleed-
ing occurred in 2 cases (18.2%), and minor bleeding in 7
cases (63.6%). Three patients were in need for pacing
(27.3%) (Table 4).
30-day follow up all cause and cardiovascular mortality
was 27.3% (n = 3) and 9.1% (n =1), respectively. One
major stroke (9.1%), 2 minor strokes (18.2%) and 3 TIAs
(27.3%) occurred. There were 1 periprocedural (<72h)
myocardial infarction (9.1%), and 1 spontaneous myocar-
dial infarctions (9.1%) requiring percutaneous coronary
intervention (PCI) at a mean follow-up of 13 days. Ten
patients (90.9%) presented combined safety endpoints.
Mean severity of heart failure according to the NYHA
functional class was 1.36 ± 0.5. Transthoracic echocardi-
ography revealed a mean AVA and aortic mean pressure
gradient of 1.8 ± 0.2 cm2 and 8.3 ± 3.9 mmHg, respect-
ively (Table 5).
At 6 months follow-up 8 patients (72.7%) were alive
without any additional myocardial infarction, pulmonary
embolism, bleeding, TIA or stroke. Mean severity of
NYHA functional class was 1.34 ± 0.7.
Table 2 Echocardiographic and electrocardiographic
parameters
Echocardiographic parameters
Left ventricular ejection fraction (%) 44.6 ± 7.8
Aortic valve area (cm2) 0.6 ± 0.2
Peak pressure gradient (mmHg) 91.0 ± 27.4
Mean pressure gradient (mmHg) 60.2 ± 13.1
Aortic annulus dimension (mm) 20.7 ± 3.5
Aortic bulbus dimension (mm) 29.7 ± 4.1
Left ventriculae end-diastolic diemater (mm) 54.6 ± 7.7
Interventricular septal dimension (mm) 13.2 ± 1.9
Aortic regurgitation, n (%) 10
Grade I 9 (81.8)
Grade II 1 (9.1)
Grade III 0
Mitral insufficiency, n (%)
Grade I 6 (54.5)
Grade II 4 (36.4)
Grade III 0
Electrocardiographic parameters
Sinus rhythm, n (%) 8 (72.7)
Atrial fibrillation, n (%) 1 (9.1)
Pacemaker, n (%) 2 (18.2)
Heart rate (bpm) 70.1 ± 10.7
PQ interval (ms) 199.4 ± 62.8
QRS width (ms) 112.6 ± 23.4
QT interval (ms) 397.5 ± 30.7
Left bundle branch block, n (%) 0 (0)
Right bundle branch block, n (%) 0 (0)
Left anterior hemiblock, n (%) 2 (18.2)
Left posterior hemiblock, n (%) 0 (0)




Male, n (%) 4 (36.4)
Age (yrs) 92.6 ± 1.3
BMI (kg/m2) 28.6 ± 3.0
Hypertension, n (%) 9 (81.8)
Dyslipidemia (%) 9 (81.8)
Smoker, n (%) 3 (27.3)
Diabetes mellitus, n (%) 7 (63.6)
Renal insufficiency (creatinine level > 1.5mg/dl), n (%) 6 (54.5)
Chronic hemodyalisis, n (%) 2 (18.2)
Chronic obstructive pulmonary disease, n (%) 2 (18.2)
New York Heart Association functional class (grade) 3.2 ± 0.8
Logistic EuroSCORE (%) 32.0 ± 9.5
STS score (%) 25.3 ± 9.7
Dyspnoe, n (%) 11 (100)
Angina, n (%) 4 (36.4)
Syncope, n (%) 4 (36.4)
Cardiac decompensation, n (%) 5 (45.5)
Pulmonal artery systolic pressure (mmHg) 40.8 ± 18.7
Porcelain aorta, n (%) 0 (0)
Ischemic heart disease, n (%) 8 (72.7)
Previous percutaneous coronary intervention, n (%) 6 (54.5)
Previous coronary artery bypass graft surgery, n (%) 4 (36.4)
Peripheral vessel disease, n (%) 2 (18.2)
Previous stroke, n (%) 2 (18.2)
Laboratory findings
Hemoglobin (mg/dl) 7.8 ± 1.2
Hematokrit (%) 37.7 ± 4.8
Creatinine (μmol/l) 183.9 ± 223.6





Beta-Blocking agent 8 (72.7)
Ca-chanel blocker 3 (27.3)
Antiarythmic agent 0 (0)
Statin 7 (63.6)
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With the ageing population the demand for cardiac
operations in elderly patients has steadily increased over
the last 10 to 15 years. Moderate-to-severe AS occurs in
5% of individuals 75 to 86 years of age, and critical AS is
seen in >5% of those >85 years of age [10]. In-hospitaldeath and stroke rates may be as high as 8.5% and 8%, re-
spectively [11]. Mean duration of postoperative hospital
stay in most reports is >2 weeks for very elderly patients,
with most being discharged to nursing care facilitates.
Today, about one third of patients with severe AS are
not referred for valve replacement surgery because of
the risk perceived by both patients and physicians. TAVI
is a robust technique, which offers advantages to high
surgical risk patients [5-7]. Elderly with AS often present
comorbidities, which are responsible for the considerable
heterogeneity of operative risk and which hamper the
decision, if the beneficial outcome of surgery, compared
with spontaneous outcome, outweighs the risk of inter-
vention. However there are no explicit age related restric-
tions for surgical aortic valve replacement according to
guidelines on treatment of severe symptomatic AS [1,11].
In nonagenarians, age alone accounts for a predicted lo-
gistic EuroSCORE mortality risk of 6.55% for male
Table 4 In-hospital outcome of patients
In-hospital outcome
Mortality, n (%)
All cause n (%) 2 (18.2)




TIA, n (%) 2 (18.2)
Myocardial infarction, n (%)
Periprocedural (<72h) 1 (9.1)
Spontaneous (>72h) 1 (9.1)
Pneumonia, n (%) 1 (9.1)
Sepsis, n (%) 1 (9.1)
Pulmonary embolism 1 (9.1)
Acute kidney injury, n (%)
Grade I 3 (27.3)
Grade II 0 (0)
Grade III 1 (9.1)
New need for hemodialysis 1 (9.1)
Bleeding, n (%)






Need for Pacing, n (%) 3 (27.3)
New left bundle branch block 6 (54.6)
New second or third-degree AV block 3 (27.3)
Need for Re-do (TAVI or Surgery) 0 (0)
Table 3 Intraoperative data of patients
Parameter
Procedural success, n (%) 11 (100)
Conversion to surgical AVR, n (%) 0 (0)
Intraprocedural circulatory depression, n (%) 1 (9.1)
Catecholamine therapy, n (%) 1 (9.1)
Resuscitation, n (%) 1 (9.1)
Defibrillation, n (%) 1 (9.1)
Vascular access site complication requiring surgery, n (%) 1 (9.1)
Contrast agent (ml) 120.9 ± 44.7
Procedure time (min) 110.3 ± 29.5




Pre TAVI valvuloplasty, n (%) 11 (100)
Post TAVI valvuloplasty, n (%) 5 (45.5)
Number of inflations after TAVI (n) 1.2 ± 0.6
Balloon diameter (mm) 20.6 ± 1.8
Balloon length (mm) 62.7 ± 16.8
Valve embolization, n (%) 2 (18.2)
Post TAVI aortic valve mean gradient 5.3 ± 4.1
Angiographic aortic insufficiency (grade) 0.9 ± 0.45
ICU stay (days) 3.36 ± 1.9
Hospital stay (days) 18.5 ± 5.4
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other preoperative risk factors [8]. In our series predicted
logistic EuroSCORE mortality rate was 32.0 ± 9.5% for
whole cohort. Feasibility of TAVI on nonagenarians was
proven by the high procedural success rate (100%). The
reduction in afterload after TAVI resulted in immediate
marked hemodynamic improvement and translated into
symptomatic relief, with a reduction in NYHA class by a
mean of 1.8 grades. We also show markedly improve-
ments in the AVA from 0.6 to 1.8 cm2 and reductions in
mean pressure gradients from 60.2 to 8.3 mmHg, which
compare favorably to the results for younger patients trea-
ted with TAVI [5,6,12,13].
Safety was assessed using primary and secondary
endpoints following recommendations of the Valve
Academic Research Consortium [9]. As there is no
trial exclusively in nonagenarians or subgroup analyses
of large trials our outcomes are not comparable with
the literature.
All-cause mortality is considered as the “gold standard”
in surgical clinical trials with cardiovascular mortality as
an important secondary endpoint [4,9,14]. In our study
the 30-day follow up all cause and cardiovascular mortal-
ity was 27.3% and 9.1%, respectively, which is slightly
higher or comparable to 11.4% to 29% all cause mortalityfor nonagenarians with low comorbidity index as stated
by the estimated logistic EuroSCORE treated with sur-
gical aortic valve replacement [15-18] and 5% to 20%
all-cause and 10% cardiovascular mortality for TAVI per-
formed at younger patients [5-7].
Like mortality, operative morbidity in the elderly is
higher than in younger patients. This is true in particular
for the frequency of stroke. Some authors have shown
that older age is strongly related to a neurological event,
the latter being associated with a previous history of
stroke and advanced atherosclerotic disease [19]. We
report one major stroke (9.1%) in our cohort, which
compares to 2.1% to 8.9% in a nonagenarian population
treated with surgical aortic valve replacement [5-7] and
0% to 10% for TAVI performed at younger patients
[5-7,13]. Our periprocedural (<72h) (9.1%), and spon-
taneous (9.1%) myocardial infarction rate is markedly
higher compared to 0% to 0.3% for TAVI performed at
Table 5 30-day follow-up of patients
30-day outcome
Mortality, n (%)
All cause n (%) 3 (27.3)




TIA, n (%) 3 (27.2)
Myocardial infarction, n (%)
Periprocedural (<72h) 1 (9.1)
Spontaneous (>72h) 1 (9.1)
New need for hemodialysis 2 (18.2)
Bleeding, n (%)






Pulmonary embolism 2 (18.2)
Combined safety endpoints 10 (90.9)
Need for Pacing, n (%) 5 (45.5)
New left bundle branch block 7 (63.7)
New second or third-degree AV block 5 (45.5)
NYHA functional class 1.36 ± 0.5
Cardiac decompensation, n (%) 2 (18.2)
Syncope, n (%) 0 (0)
Need for hospitalization due to cardiac causes, n (%) 3 (27.2)
Need for Re-do (TAVI or Surgery) 0 (0)
Echocardiographic parameters
Left ventricular ejection fraction (%) 45.6 ± 6.9
Left ventriclura end-diastolic diameter (mm) 50.1 ± 7.1
Aortic valve area (cm2) 1.8 ± 0.2
Aortic peak pressure gradient (mmHg) 16.6 ± 6.7
Aortic mean pressure gradient (mmHg) 8.3 ± 3.9
Interventricular septal dimension (mm) 13.5 ± 1.6
Aortic regurgitation, n (%)
Grade I 9 (81.9)
Grade II 2 (18.2)
Grade III 0 (0)
Pulmonal artery systolic pressure 45.7 ± 14.6
Mitral insufficiency (%)
Grade I 8 (72.8)
Grade II 2 (18.2)
Grade III 0 (0)
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replacement performed at nonagenarians [16] pointing
out the high cardiovascular risk profile of our severely
ill patients. Two life-threatening or disabling bleeding
occurred (18.2%) which compares favorably to rates of
3.6% to 24% for TAVI performed at younger patients
[5-7,13]. Vascular complications after TAVI occur with
an incidence of 7.5% to 16.3% and remain a significant
cause of mortality and morbidity [5-7,13]. We report
similar rates of major and minor vascular complica-
tions. 3 patients presented acute kidney injury grade I
(27.3%), and one patient grad III (9.1%), which is com-
parable to 6% to 28% of acute kidney injuries reported
in the literature [20].
As shown in previous studies, the very elderly are
more likely to experience postoperative complications,
and consequently, a prolonged hospitalization and inten-
sive therapy [21,22]. However, the length of hospital and
ICU stay reported in our study (18.5 ± 5.4 and 3.36 ± 1.9
days respectively) is comparable to data for younger
patients (7 to 17 days and 2.8 days respectively [23].
In general population, life expectancy in nonagenar-
ians is 2.5 and 3.5 years for men and women, respect-
ively [24]. Although one should take into account the
very advanced age and frailty of these subjects in the in-
terpretation of such results, all-cause death is still not
low despite successful TAVI. However, the patients who
survived the follow-up achieved in most cases an im-
provement in their clinical symptoms. Thus, TAVI in the
very elderly have the potential to significantly ameliorate
functional status and quality of life, at the price of con-
siderable periinterventional and follow-up mortality
rates. The risk-benefit balance of TAVI of nonagenarians
should then be considered to be paradigmatically differ-
ent than in the younger candidates, in whom the pro-
longation of life is usually considered the primary aim.
The clinician should consider these findings while evalu-
ating the very elderly for TAVI and properly discuss
these issues in the light of the patient’s expectations.Conclusions
Our case series demonstrate that even with elevated
comorbidity index clinical endpoints and valve-associated
results are relatively favorable in nonagenarians treated
with CoreValve prosthesis. Due to the small sample size
there is a need for more data from multicenter large-scale
trials or registries to elucidate the role of TAVI in nona-
genarian patients.Abbreviations
AS: Aortic stenosis; AVA: Aortic valve area; AVR: Aortic valve replacement;
ECG: Electrocardiography; ICU: Intensive care unit; NYHA: New York Heart
Association; PCI: Percutaneous coronary intervention; TAVI: Transcatheter
aortic valve implantation.
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